AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 294: H2002-H2011, 2008. First published February 29, 2008; doi:10.1152/ajpheart.00762.2007
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/5/H2002    most recent
00762.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Schuleri, K. H.
Right arrow Articles by Hare, J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schuleri, K. H.
Right arrow Articles by Hare, J. M.

CALL FOR PAPERS
Cardiovascular-Renal Mechanisms in Health and Disease

Early improvement in cardiac tissue perfusion due to mesenchymal stem cells

Karl H. Schuleri,1,2 Luciano C. Amado,1,2 Andrew J. Boyle,1 Marco Centola,1,2 Anastasios P. Saliaris,1,2 Matthew R. Gutman,1,2 Konstantinos E. Hatzistergos,4 Behzad N. Oskouei,1,2,4 Jeffrey M. Zimmet,1 Randell G. Young,3 Alan W. Heldman,1,4 Albert C. Lardo,1 and Joshua M. Hare1,2,4

1Division of Cardiology, Department of Medicine and 2Institute for Cell Engineering, Johns Hopkins University School of Medicine and 3Osiris Therapeutics, Incorporated, Baltimore, Maryland; and 4Cardiovascular Division, Department of Medicine and Interdisciplinary Stem Cell Institute, University of Miami, Miami, Florida

Submitted 2 July 2007 ; accepted in final form 4 February 2008

The underlying mechanism(s) of improved left ventricular function (LV) due to mesenchymal stem cell (MSC) administration after myocardial infarction (MI) remains highly controversial. Myocardial regeneration and neovascularization, which leads to increased tissue perfusion, are proposed mechanisms. Here we demonstrate that delivery of MSCs 3 days after MI increased tissue perfusion in a manner that preceded improved LV function in a porcine model. MI was induced in pigs by 60-min occlusion of the left anterior descending coronary artery, followed by reperfusion. Pigs were assigned to receive intramyocardial injection of allogeneic MSCs (200 million, ~15 injections) (n = 10), placebo (n = 6), or no intervention (n = 8). Resting myocardial blood flow (MBF) was serially assessed by first-pass perfusion magnetic resonance imaging (MRI) over an 8-wk period. Over the first week, resting MBF in the infarct area of MSC-treated pigs increased compared with placebo-injected and untreated animals [0.17 ± 0.03, 0.09 ± 0.01, and 0.08 ± 0.01, respectively, signal intensity ratio of MI to left ventricular blood pool (LVBP); P < 0.01 vs. placebo, P < 0.01 vs. nontreated]. In contrast, the signal intensity ratios of the three groups were indistinguishable at weeks 4 and 8. However, MSC-treated animals showed larger, more mature vessels and less apoptosis in the infarct zones and improved regional and global LV function at week 8. Together these findings suggest that an early increase in tissue perfusion precedes improvements in LV function and a reduction in apoptosis in MSC-treated hearts. Cardiac MRI-based measures of blood flow may be a useful tool to predict a successful myocardial regenerative process after MSC treatment.

myocardial blood flow; perfusion magnetic resonance image; neovascularization; myocardial infarction; allogeneic



Address for reprint requests and other correspondence: J. M. Hare, Clinical Research Bldg., 1120 NW 14th St., Ste. 1124, Miami, FL 33136 (e-mail: JHare{at}med.miami.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.